Purpose: ALK rearrangement detection using FISH is the standard test to identify patients with non-small cell lung carcinoma (NSCLC) eligible for treatment with ALK inhibitors. Recently, ALK protein expression in resectable NSCLC showed predictive value. We evaluated tumor response rate and survival after crizotinib treatment of patients with advanced NSCLC with ALK activation using both dichotomous immunohistochemical (IHC) staining and FISH.
Introduction
In 2007, the first report of an echinoderm microtubule-associated protein like 4 -anaplastic lymphoma kinase (EML4/ALK) fusion gene on chromosome 2p in lung cancer has been published (1). EML4/ALK variants with different breakpoints and other fusion partners for ALK have been identified, for example, KIF5B, TRK, TPR, KLC1, DCTN, and SQSTM (1-4). EML4/ALK rearrangement occurs in approximately 5% of patients with advanced non-squamous non-small cell lung carcinoma (NSCLC; refs. 1, 5-7). In stages I to III, NSCLC ALK rearrangement frequency is 3.2% (8) .
In 2010, crizotinib has been registered as the first drug for treating EML4/ALK-positive patients with advanced NSCLC. Phase II studies in patients with ALK-break-positive NSCLC defined by FISH revealed tumor response rates up to 65% (4, 9) . Phase III studies confirmed the response rate and showed an improved survival compared with chemotherapy (10) . In these studies, no major differences were observed between ALK rearrangements, expression of fusions at RNA, and ALK detection at protein level. However, the explanation why some patients with an ALK rearrangement did not respond to initial ALK inhibitors was not solved.
In the United States, the CE-IVD-marked Abbott FISH kit was registered as a companion diagnostic for crizotinib. The Ventana ALK (D5F3) CDx assay is approved as a CE-IVD in Europe, China (www.ventana.com), and the United States (www.fda.gov) since 2012, 2013, and June 2015, respectively. This test is used on a fully automatic BenchMark XT and with a dichotomous scoring system. This test is unambiguous and only provides a positive or negative outcome (11) . In Japan, ALK-RT-PCR is most commonly used in the diagnosis of ALK status (12) . In Europe, the European Medicines Agency (EMA) allows the use of clinically validated methods to detect ALK positivity either by FISH or IHC. The FDA-approved Abbott break-apart ALK-FISH probe and scoring using the international guidelines (www.Abbott.com) is labor-intensive, timeconsuming, and operator-dependent (13) . Furthermore, the detection of ALK rearrangements by FISH is not always concordant with ALK protein expression, although most studies show a concordance close to 100% (7, 8, 12, 14, 15) .
Recently, several articles have been published on the comparison of different ALK-IHC and ALK-FISH tests. Most of these studies used resection samples of which tissue microarrays (TMA) were made (8, 12, 14, 15) . In those studies only few patients have been treated with crizotinib, probably at recurrence of disease. In clinical practice, however, most patients with ALK-positive NSCLC present with stage IV disease upon diagnosis. This is often based on small biopsies and/or fine-needle aspiration (FNA), which is usually not enough to build TMAs. In previous studies, tests have been compared without investigating the predictive value for treatment outcome.
Therefore, we explored the predictive value of Ventana ALK (D5F3) CDx assay and the Abbott break-apart ALK-FISH test, on small biopsies and FNA, taken for predictive screening in our referral center. Cases were those who routinely tested and those where the interpretation of the FISH test result was difficult for tumor response to crizotinib in patients with stage IV NSCLC. We hypothesized that dichotomous ALK-IHC, measuring the expression of the ALK protein containing the active kinase part, has a better predictive value than ALK-FISH for ALK-positive patients with high tumor responses and prolonged survival (11) .
Materials and Methods
Patients Screening group. All consecutive patients with stage IV non-squamous carcinoma tested in our national referral center for ALK-FISH testing resulted in a selected cohort of cases who had a positive ALK test either by ALK-FISH or dichotomous ALK-IHC scoring algorithm. Consecutive patients were those with routinely established FISH and a highly selected group with difficult interpretable FISH test results. From 2013 in parallel to ALK-FISH, analysis was performed with Ventana ALK-IHC. Tissue blocks were collected from all patients with ALK-FISH-positive tumors, but without ALK-IHC data (mainly before 2013), used for ALK-FISH, and when sufficient neoplastic cells were present, dichotomous ALK-IHC was performed. Twenty-nine ALK-positive patients (either FISH or IHC positive) were treated with ALK inhibitors and prospectively evaluated for patients' characteristics, for example, smoking and performance score, and treatment outcome. Tumor response was assessed on CT using RECIST 1.1 (16) .
External validation group. An external validation set of ALK-FISHpositive tumor samples from patients treated with crizotinib in 4 other hospitals was collected. To exclude laboratory quality differences (e.g., FISH operator dependency) between hospitals as potential bias, exchange of tumor samples and test results is necessary. The samples were tested with the dichotomous ALK-IHC at University Medical Centre Groningen (UMCG; Groningen, the Netherlands). Response rates, duration of crizotinib treatment, and survival were compared with dichotomous ALK-IHC results.
Detection of ALK status by FISH
FISH was performed with the commercial LSI ALK dual-color, break-apart rearrangement probe kit (Abbott Molecular Inc. 06N38-020) for the evaluation of ALK genomic status (ALK-FISH). In brief, 4-mm formalin-fixed, paraffin-embedded (FFPE) tissue or CytoLyt block sections were mounted on positively charged glass slides and dried overnight at 60 C. Areas with sufficient neoplastic cells were marked after review of the corresponding hematoxylin and eosin (H&E) slide by a pathologist. After deparaffinization, slides were pretreated in Tris-EDTA, pH 9.0, buffer at 120 C for 7 minutes in a pressure cooker, washed and incubated in RNase (0.1 mg/mL diluted in 2Â SSC) at 37 C for 1 hour, washed again, and treated with pepsin (0.1% diluted in 0.01 N HCl) at 37 C for 10 minutes (biopsies and FNA: 5 minutes); denaturation (12 minutes at 80 C) and hybridization (overnight at 37 C) were performed. After hybridization, slides were washed 2Â SSC/0.3% NP-40 at 73 C for 2 minutes followed by 2Â SSC/0.1% NP-40 for 1 minute at room temperature, dehydrated, air-dried (2Â alcohol 96% and air-dried), and finally, slides were mounted manually in Vectashield with 4 0 ,6-diamidino-2-phenylindole (DAPI; 0.33 mg/mL diluted in Vectashield). Stained sections were stored at 2 C to 8 C in the dark until evaluation was performed to prevent fading of the fluorescent signals. Using the appropriated filters, scoring was performed according to the international guidelines (www.Abbott.com; ref. 13 ) and analyzed independently by 2 experienced FISH Translational Relevance ALK rearrangement detection using FISH is the standard test to identify patients with non-small cell lung carcinoma (NSCLC) eligible for treatment with ALK inhibitors. Recently, ALK protein expression in resectable NSCLC showed predictive value. In this study, we evaluated tumor response rate and survival after crizotinib treatment of patients with advanced NSCLC with ALK activation using both dichotomous immunohistochemical (IHC) staining and FISH. We have found that dichotomous ALK-IHC is superior to ALK-FISH on small biopsies and fine-needle aspirations (FNA) to predict tumor response and survival to crizotinib for patients with advanced NSCLC. Our data strongly suggest adapting the guidelines and using dichotomous ALK-IHC as standard companion diagnostic test to select patients with NSCLC who benefit from ALK-targeting therapy.
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on June 19, 2017. © 2017 American Association for Cancer clincancerres.aacrjournals.org Downloaded from evaluators. A case was considered ALK-FISH-positive when more than 15% of the evaluated 100 neoplastic nuclei had the breakapart pattern. In case of discordance, a third independent experienced assessor scored the sample. FISH was performed in the laboratory of Molecular Pathology Department at the UMCG. Moreover, in case, enough tumor tissue was present, ALK-FISH was also performed at an international ALK-FISH laboratory (Dr. P. Pauwels, Antwerp, Belgium) to confirm our test data.
The ALK-FISH for the external validation cohort was performed in the local laboratories of Maastricht University Medical Centre (MUMCþ; Maastricht, the Netherlands), ZGT (Hengelo, the Netherlands), Vanderbilt University Medical Center (VUMC; Nashville, TN), and Radboud UMC (Nijmegen, the Netherlands).
Detection of ALK expression status by immunohistochemistry and dichotomous scoring
ALK-IHC was performed on 4-mm-thick FFPE tissue sections or CytoLyt block sections using the Ventana ALK (D5F3) CDx assay on a Ventana BenchMark XT automated slide-processing system (Ventana Medical Systems Inc.). Briefly, slides of NSCLC tumor were subjected to deparaffinization using EZ Prep (VMSI) and 
Validation of the fusion products by RT-PCR
cDNA was synthesized using 500 ng total RNA input with Superscript II reverse transcriptase and random primers according to the company instruction (Invitrogen). PCR was performed using 10 ng cDNA as input in a final volume of 30 mL containing 1Â PCR buffer and MgCl 2 (final concentration. 1.5 mmol/L), 0.2 mL Taq DNA polymerase (5 unit/mL; Invitrogen), and 10 mmol/L primers designed using Clone Manager Suite (Sci-Ed Software). Amplification consisted of 45 cycles using a thermocycler (Bio-Rad). Primers detecting the known EML4/ALK fusion variants are listed in Supplementary Table S1 .
Statistical analysis
Statistics for patient characteristics were descriptive and c 2 test was used for comparison. ALK test performance of FISH and the dichotomous IHC for screening and validation were compared with receiver operating characteristics (ROC) method with primary outcome tumor response and survival. To test for confounders, uni-and multivariate analyses were performed. Progressionfree survival (PFS) was defined from the date of treatment start until the date of disease progression or death. Overall survival (OS) was defined from treatment start until the date of death. To compare survival of different groups by Kaplan-Meier method, log-rank test was used. For evaluating the influence of the percentage of breaks by FISH on PFS and OS, t test was used. P < 0.05 was considered significant. Statistical analyses were performed with SPSS 22.0.
Results
Between January 2011 and July 2015, 29 patients with advanced non-squamous NSCLC showed a positive ALK status (Supplementary Fig. S1 ), based on ALK-FISH (n ¼ 16), ALK-IHC (n ¼ 3), or both (n ¼ 10). They were selected at a University Medical Center and treated with crizotinib with a median follow up of 5.8 months [95% confidence interval (CI), 0.0-15.4]. In 22 of 29 patients, ALK tests were performed on endobronchial biopsies or transthoracic punctures and in 8 patients on FNA obtained by endoscopic ultrasound and/or endobronchial ultrasound. The median age of the screening cohort was 58 years (range, 21-79). Twenty patients were diagnosed with adenocarcinoma and 10 with NSCLC favoring adenocarcinoma. Most patients were non-smokers (9 of 29) or previous smokers (11 of 29) and had a good performance score of 0 to 1 (Table 1) . Crizotinib (250 mg twice a day) was used as the second-line treatment after chemotherapy in 22 of 29 patients and in others as first-line therapy.
Treatment response of patients with ALK-positive NSCLC as determined by break-apart FISH analysis
Twenty-six of 29 patients were ALK-FISH-positive with more than 15% of 100 neoplastic nuclei with break-apart pattern. Response rate (RR) in the FISH-positive group, including 13 dichotomous ALK-IHC-negative patients, was low (23%); the median PFS (mPFS) was 1.8 months (95% CI, 1.4-2.2) and median OS (mOS) was 5.3 months (95% CI, 0.0-15.4). Three patients who were dichotomous ALK-IHC-positive and FISHnegative had a RR of 67% with an mPFS of 5.0 months (95% CI, 0.0-11.2) and mOS of 5.8 months (95% CI, 0.5-11.1).
The median percentage of neoplastic nuclei with ALK breaks was 35% (range, 2%-78%). No association was observed between the percentage of ALK breaks and treatment outcome as determined by RR, PFS, and OS (Table 2) . Also, cases with ALK rearrangement based on the loss of the 5 0 -ALK-FISH probe resulting in the typical pattern with a single red FISH signal were found in 6 of 29 patients. This pattern was not associated with a better treatment outcome. The international ALK-FISH referral center confirmed our ALK-FISH data in 14 cases of which enough tumor was present.
Treatment response of dichotomous patients with ALK-IHCpositive NSCLC
In 26 of 29 patients, tumor tissue with sufficient neoplastic cells was left to perform the dichotomous ALK-IHC test. Thirteen tumors showed ALK expression whereas 13 were negative (all 13 were ALK-FISH-positive). In the dichotomous ALK-IHC-positive group, the RR was 69% with an mPFS of 8.4 months (95% CI, 3.1-13.7) and an mOS of 18.3 months (95% CI, 12.4-24.2). No responses were observed in the dichotomous ALK-IHC-negative group with an mPFS of 1.5 months (95% CI, 0.9-2.1) and an mOS of 5.0 months (95% CI, 4.3-5.7). Univariate and multivariate analyses revealed that dichotomous ALK-IHC was associated with better treatment outcome as determined by tumor response (P < 0.001), mPFS (P < 0.001), and mOS (P ¼ 0.01). The duration of tumor responses is outlined in Fig. 1 .
Three patients with dichotomous ALK-IHC-positive tumor had no response to crizotinib, 1 patient died because of complications of brain radiotherapy shortly after starting crizotinib (ALK24). One patient died because of liver failure due to metastases with necrosis on therapy (ALK20). In another patient, only a part of the tumor at the border of the tissue section showed ALK-FISH positivity while most neoplastic cells were ALK-FISH negative. Retesting of the residual tissue using both ALK-FISH and dichotomous ALK-IHC revealed that the earlier observed FISH-positive tumor area was not present anymore. All neoplastic cells were negative for both ALK-FISH and dichotomous ALK-IHC (ALK09; Fig. 2A ). This could explain lack of tumor response. In the third resistant patient (ALK 21; Fig. 2B ), dichotomous ALK-IHC showed heterogeneous immunostaining of the neoplastic cells. Since all other dichotomous ALK-IHC-positive cases in this study showed a homogeneously strong ALK expression of all neoplastic cells (see Fig. 2C and D for examples) , the presence of the ALK-negative neoplastic cells in case ALK21 might explain the short PFS.
One patient (ALK 10) without tumor response had stable disease for 10 months.
Comparison of break-apart FISH, EML4/ALK-RT-PCR and dichotomous ALK-IHC
Comparison of both dichotomous ALK-IHC and ALK-FISH test performances showed a better prediction of tumor response shifting the ROC from 0.64 to 0.86 (P ¼ 0.03) in favor of dichotomous ALK-IHC (Fig. 3) . This has been observed for survival outcomes as well. Using PFS as the primary outcome, ROC increased from 0.36 to 0.86 (P ¼ 0.005), and for OS, ROC increased from 0.41 to 0.78 (P ¼ 0.01). When dichotomous ALK-IHC and ALK-FISH data were combined, tumor response and survival were associated with ALK-IHC, independent of ALK-FISH outcome in multivariate analysis. Dichotomous ALK-IHC outcome was not associated with the percentage of neoplastic nuclei with ALK break-apart patterns (range, 2%-78%; Supplementary  Fig. S2 ) which is in line with a previous study (17) .
To explain the discrepancy between FISH and IHC, we performed RT-PCR or exome sequencing. In one patient (ALK04), RT-PCR confirmed the presence of ALK rearrangement (E20; A20, Dichotomous ALK-IHC is depicted as positive (green) or negative (red) for tumor response outcome, measured on CT using RECIST 1.1. Tumor progression is determined when there is >20% increase in size, partial response is determined when there is >30% decrease in size, stable disease is determined between 20% increase and 30% decrease in size. Time of tumor response is in weeks. †, deceased; z, progressive disease due to new lesion. Research.
on June 19, 2017. © 2017 American Association for Cancer clincancerres.aacrjournals.org Downloaded from variant 2) that was not detected by ALK-FISH. This patient had one of the longest PFS in our treatment cohort (15.9 months). Patient (ALK09) was positive for ALK-FISH in a small area of neoplastic cells only (<2%). Dichotomous ALK-IHC and EML4/ALK-RT-PCR were both negative on the same tissue block that did not contain the earlier small FISH-positive area anymore. This patient did not respond to crizotinib. In 2 patients, dichotomous ALK-IHC could not be performed, ALK-FISH was positive, and EML4/ALK-RT-PCR was negative. Both patients did not respond to crizotinib.
In 5 responding patients, all 3 tests (dichotomous ALK-IHC, ALK-FISH, ALK-RT-PCR) were positive ( Table 2) .
Validation cohort of dichotomous ALK-IHC compared with response
In the 4 Dutch hospitals 53 patients were treated with crizotinib on the basis of a positive ALK-FISH (Supplementary Fig. S1 ). Of those, 16 patients had enough tumor tissue available to perform the dichotomous Ventana (D5F3) ALK-IHC. Eleven patients had a positive dichotomous ALK-IHC and 5 were negative. All 5 dichotomous ALK-IHC-negative patients did not have a response to crizotinib. Response percentage in the IHC-positive patients was 72. Three positive patients showed stable disease and 8 of 11 patients had a partial or complete response with crizotinib (Table 3) .
Discussion
This is the first systematic study in advanced NSCLC with small amounts of tumor tissue to compare the value of the dichotomous ALK-IHC and ALK-FISH test on the basis of tumor response and survival as primary outcome. The dichotomous ALK-IHC largely outperformed the ALK-FISH as measured by ROC in a screening (one hospital) and validation (4 other hospitals) cohort of patients with advanced ALK-positive NSCLC. All patients with a negative dichotomous ALK-IHC did not respond to crizotinib. Therefore, patients who were tested with the Ventana ALK (D5F3) IHC did not need additional ALK-FISH testing. This is in contrast to current guidelines (e.g., CAP/IASL/AMP 2013) that ALK-FISH is required to confirm ALK-IHC status. We demonstrated that these guidelines would even harm ALK-IHC-positive/ALK-FISH-negative patients from not receiving the appropriate ALK inhibitors.
Despite the large number of reports on the prevalence of ALK positivity in NSCLC and the comparison of various detection assays, few studies report on the optimal biomarker predicted by tumor response to ALK inhibitors. ALK-IHC with 5A4 antibodies were used in comparison with Vysis FISH in a French Source of the curve FISH percentage ALK-IHC Figure 3 . ROC plot of dichotomous ALK-IHC Ventana and the Abbott break-apart ALK-FISH to predict tumor response to crizotinib. In our cohort, there were ALK-FISH-positive patients without a tumor response to crizotinib while all except 2 patients with dichotomous ALK-IHC responded. The ROC curves with survival as endpoint were similar. P value relates to comparison with area under the ROC curve of 0.5. study of 45 patients, an Italian study with the ETOP consortium, and a Japanese study (7, 12, 14) . Importantly, none of these studies took patient outcome as a measurement of test efficacy. Other ALK-IHC and ALK-FISH tests are described in Supplementary File. The low response rate for the whole group was due to a substantial number of patients with ALK-FISH-positive and ALK-IHC-negative patients, indicating a selected population. All those patients did not respond to crizotinib. The higher frequency of these patients was due to the fact that our center not only performs routinely FISH testing but also difficult interpretable FISH testing. Therefore, we confirmed our ALK-FISH results in the international ALK-FISH center. The dichotomous ALK-IHCpositive group showed response rates and survival comparable to second-line treatment as shown in the studies by Kwak and colleagues and Shaw and colleagues (4, 10) . Moreover, 2 dichotomous ALK-IHC-positive but ALK-FISH-negative patients responded to crizotinib. This is similar as in a study by Pekar and colleagues, where 2 such patients also responded to crizotinib. These (ALK-IHC-positive and ALK-FISH-negative) patients showed an ALK translocation as measured with next-generation sequencing (NGS; ref. 18 ). Other patient reports showed a similar outcome (14, 19, 20) .
Comparison of ALK expression levels with the presence of ALK rearrangements detected with FISH revealed an agreement between 90% and 100% (11, (21) (22) (23) (24) (25) (26) (27) (28) .
Occasionally, patients have been described who were ALK-FISH-positive but ALK-IHC-negative and who responded to crizotinib. Ilie and colleagues showed 3 patients (EML4/ALK break RT-PCR-negative also) who responded due to the fact that they were cMET amplification-positive, as crizotinib is a MET inhibitor as well (29) . This could also be the case for the patient mentioned in the article by Marchetti and colleagues (8) , although this was not evaluated.
We also showed that heterogeneous staining was only observed in patients who did not respond to treatment. So, only those patients respond effectively to ALK treatment who have a homogenously positive dichotomous ALK-IHC staining.
In conclusion, this is the largest report where dichotomous ALK-IHC and FISH tests are evaluated in small biopsies and cytology alone. Dichotomous ALK-IHC (either positive or negative) outcome is superior to ALK-FISH on small biopsies and FNA to predict tumor response and survival to anti-ALK therapy for patients with advanced NSCLC. Our data strongly suggest that guidelines should be adapted, and dichotomous ALK-IHC should be the standard companion diagnostic test to select patients with NSCLC who benefit from anti-ALK therapy.
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